HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $32.
September 11, 2023 | 10:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $32.
The reiteration of the 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Verona Pharma. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100